Suppliers and packagers for RILUZOLE

RILUZOLE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Alkem Labs Ltd	RILUZOLE	riluzole	TABLET;ORAL	204048	ANDA	Ascend Laboratories, LLC	67877-286-05	500 TABLET in 1 BOTTLE (67877-286-05)	2016-03-31
Alkem Labs Ltd	RILUZOLE	riluzole	TABLET;ORAL	204048	ANDA	Ascend Laboratories, LLC	67877-286-10	1000 TABLET in 1 BOTTLE (67877-286-10)	2016-03-31
Alkem Labs Ltd	RILUZOLE	riluzole	TABLET;ORAL	204048	ANDA	Ascend Laboratories, LLC	67877-286-14	10 BLISTER PACK in 1 CARTON (67877-286-14) / 14 TABLET in 1 BLISTER PACK	2016-03-31

Riluzole Manufacturing and Supply Chain Landscape

Last updated: February 19, 2026

This report analyzes the global supply chain for Riluzole, a critical medication used in the treatment of Amyotrophic Lateral Sclerosis (ALS). It identifies key manufacturers, examines production capacities, and assesses potential supply risks based on patent expirations, regulatory landscapes, and geopolitical factors.

What are the primary active pharmaceutical ingredient (API) manufacturers for Riluzole?

The global production of Riluzole API is concentrated among a limited number of specialized chemical manufacturers. These companies possess the technical expertise and regulatory compliance required for pharmaceutical-grade API synthesis. Key players include:

• Zhejiang NHU Co., Ltd. (China): A significant producer of Riluzole API. The company is a large-scale chemical manufacturer with established GMP (Good Manufacturing Practice) certifications.
• Abbott Laboratories (United States): While Abbott is the originator of Riluzole (marketed as Rilutek), its role in direct API manufacturing for the global market has evolved. They retain significant API production capabilities.
• Dr. Reddy's Laboratories (India): A major Indian pharmaceutical company with robust API manufacturing facilities. Dr. Reddy's is known for producing a wide range of APIs, including those for neurological disorders.
• Sun Pharmaceutical Industries Ltd. (India): Another prominent Indian pharmaceutical firm actively involved in API production. Sun Pharma has a broad portfolio and a strong presence in global pharmaceutical markets.
• Various European and Asian Chemical Manufacturers: Several smaller to medium-sized specialized chemical synthesis companies in Europe and other parts of Asia also contribute to the Riluzole API supply, often through contract manufacturing. These entities may not be as publicly prominent but play a vital role in the overall supply chain.

The production of Riluzole API involves multi-step organic synthesis. Typical precursors can include guanidine and aminophenol derivatives. The process requires stringent quality control to meet pharmacopoeial standards (e.g., USP, EP, JP). Manufacturing yields and purity are critical metrics for API suppliers. For instance, typical Riluzole API purity specifications exceed 99.5% with strict limits on specific impurities, often in the parts-per-million range.

Who are the primary finished dosage form (FDF) manufacturers of Riluzole?

The finished dosage form manufacturing of Riluzole, typically as 50 mg tablets, involves companies that formulate the API into a final product. This landscape includes both originator companies and numerous generic manufacturers.

• Originator:

  • Sanofi S.A. (France): The current marketing authorization holder for Rilutek® in many major markets. Sanofi is involved in the formulation and distribution of the branded product.

• Generic Manufacturers (Representative List):

  • Teva Pharmaceutical Industries Ltd. (Israel): A leading global generic pharmaceutical company with Riluzole tablets in its portfolio.
  • Mylan N.V. (now part of Viatris) (United States/Netherlands): A significant player in the generics market, offering Riluzole.
  • Sun Pharmaceutical Industries Ltd. (India): As with API, Sun Pharma also manufactures and markets generic Riluzole tablets.
  • Dr. Reddy's Laboratories (India): Also produces generic Riluzole tablets for various markets.
  • Aurobindo Pharma Limited (India): Another prominent Indian generic manufacturer with Riluzole formulations.
  • Accord Healthcare (United Kingdom): A European generic company that supplies Riluzole in the UK and other European countries.
  • Canadian and Australian Generic Companies: Numerous smaller and regional generic manufacturers in countries like Canada and Australia also market Riluzole, catering to local healthcare systems.

The manufacturing of FDF requires facilities that comply with cGMP standards, adhere to strict packaging and labeling requirements, and undergo rigorous batch testing for dissolution, uniformity of dosage units, and stability.

What is the patent landscape for Riluzole, and when did key patents expire?

The patent landscape for Riluzole is characterized by the expiration of its primary composition of matter and method of use patents, paving the way for generic competition.

• Original Composition of Matter Patent: Filed by Rhône-Poulenc (later Aventis, now Sanofi). The original U.S. patent for Riluzole was granted in the early 1990s. Key patents generally expire 20 years from the filing date, although extensions and data exclusivity periods can influence market exclusivity.

  • U.S. Patent 4,732,906: This foundational patent related to Riluzole was filed in 1986 and expired in 2006 after its 20-year term.
  • European Patents: Corresponding patents in Europe also expired in the mid-2000s, enabling generic market entry in the EU. For example, European Patent EP0128813B1, related to Riluzole, expired around 2005-2006.

• Method of Use Patents: While the composition of matter patent is primary, patents covering specific therapeutic uses, dosages, or formulations can extend market exclusivity. However, for Riluzole, the primary therapeutic indications have been well-established, and these method of use patents have also largely expired or been successfully challenged by generic manufacturers.

• Exclusivity Periods: Beyond patent expiry, regulatory exclusivities (e.g., Hatch-Waxman exclusivity in the U.S., data exclusivity in the EU) provide additional periods of market protection for the innovator drug.

  • In the U.S., Rilutek® benefited from New Chemical Entity (NCE) exclusivity, which typically lasts 5 years from approval. Given Riluzole's initial approval dates (e.g., 1995 in the U.S.), this exclusivity would have concluded by 2000.
  • However, the 20-year patent term from filing date is the dominant factor for generic entry for the core molecule. Therefore, generic Riluzole began appearing in significant numbers in markets like the U.S. and Europe around 2006-2008, following the expiry of the foundational patents.

The expiration of these core patents has led to a highly competitive generic market for Riluzole.

What are the regulatory considerations for Riluzole manufacturing and supply?

Regulatory compliance is paramount for all entities involved in the Riluzole supply chain. Key considerations include:

• Good Manufacturing Practice (GMP): All API and FDF manufacturers must adhere to GMP guidelines established by regulatory authorities such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. Compliance involves rigorous quality control, process validation, facility maintenance, and personnel training.
• Drug Master Files (DMFs) / Active Substance Master Files (ASMFs): API manufacturers submit DMFs (in the U.S.) or ASMFs (in Europe) to regulatory agencies. These confidential documents contain detailed information about the API manufacturing process, quality controls, and facility. FDF manufacturers reference these filings in their drug product applications.
• ANDA/MAA Filings: Generic FDF manufacturers must submit Abbreviated New Drug Applications (ANDAs) in the U.S. or Marketing Authorisation Applications (MAAs) in Europe. These applications demonstrate bioequivalence to the reference listed drug (RLD) and compliance with all regulatory requirements.
• Pharmacopoeial Standards: Riluzole API and finished products must meet the specifications outlined in relevant pharmacopoeias, such as the United States Pharmacopeia (USP), European Pharmacopoeia (EP), and Japanese Pharmacopoeia (JP). These standards define acceptable limits for purity, impurities, dissolution, and other critical quality attributes.
• Country-Specific Registrations: Manufacturers and distributors must obtain marketing authorizations in each country or region where Riluzole products are sold. This involves navigating diverse regulatory requirements and submission processes.
• Supply Chain Security and Traceability: With the rise of counterfeiting and diversion, regulations increasingly focus on supply chain integrity. Measures like serialization and track-and-trace systems are becoming mandatory in many jurisdictions to ensure product authenticity from manufacturer to patient.
• Environmental, Health, and Safety (EHS) Regulations: Chemical synthesis of APIs involves the use of hazardous materials and processes. Manufacturers must comply with strict EHS regulations to ensure worker safety and minimize environmental impact.

What are the potential risks and challenges in the Riluzole supply chain?

The Riluzole supply chain, while established, faces several potential risks and challenges:

• API Supplier Concentration: The reliance on a limited number of key API manufacturers, particularly in specific geographic regions (e.g., China, India), creates vulnerability to supply disruptions. Geopolitical tensions, natural disasters, or sudden regulatory crackdowns in these regions can impact global availability.
• Quality Control Failures: Any lapse in quality control by an API or FDF manufacturer can lead to product recalls, regulatory sanctions, and significant reputational damage. Batch failures or the discovery of unacceptably high impurity levels can halt production.
• Regulatory Scrutiny: Increased regulatory oversight, particularly concerning impurity profiles (e.g., nitrosamines), can lead to manufacturing process changes, extended review times, and potential market withdrawals if non-compliance is found. The regulatory environment is dynamic.
• Logistical Bottlenecks: Global shipping delays, port congestion, and transportation cost volatility can impact the timely delivery of both API and finished products. The COVID-19 pandemic highlighted the fragility of global logistics networks.
• Price Pressures and Competition: The highly competitive generic market can lead to significant price erosion, impacting the profitability of manufacturers and potentially reducing incentives for investment in capacity or quality improvements. This can also lead to some smaller manufacturers exiting the market.
• Raw Material Sourcing: Fluctuations in the availability and cost of key starting materials and reagents used in Riluzole synthesis can affect production costs and supply continuity.
• Geopolitical Instability: Trade wars, tariffs, or regional conflicts can disrupt cross-border movement of raw materials and finished goods, impacting the global supply of Riluzole.
• Emergence of New Therapies: While Riluzole is a cornerstone treatment for ALS, the development of novel therapies could potentially impact its long-term market share and production volumes, though it is likely to remain a critical treatment for the foreseeable future.

What are the geographical hubs for Riluzole manufacturing?

The manufacturing of Riluzole, both API and FDF, is geographically diversified but with significant concentrations in specific regions known for their pharmaceutical and chemical industries.

• India: A dominant hub for both Riluzole API and generic FDF manufacturing. Indian companies benefit from strong chemical synthesis expertise, cost-effective manufacturing, and a well-established regulatory framework for exports.
  • Key Companies: Dr. Reddy's Laboratories, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited.
• China: A major global supplier of Riluzole API. Chinese chemical manufacturers are known for large-scale production capacity and competitive pricing.
  • Key Companies: Zhejiang NHU Co., Ltd.
• United States: Home to the originator company (historically Abbott, now Sanofi's role in FDFs) and several API and FDF manufacturers. The U.S. market also sees significant generic production.
  • Key Companies: Abbott Laboratories (API), Viatris (FDF).
• Europe (primarily Western Europe): Hosts some originator manufacturing and a segment of specialized API and generic FDF producers. European manufacturers often emphasize high-quality standards and adherence to strict EMA regulations.
  • Key Companies: Sanofi S.A. (FDF), Accord Healthcare (FDF).
• Other Asian Countries: Countries like South Korea and Taiwan may host specialized chemical synthesis companies that contribute to the Riluzole API supply chain.

The distribution of manufacturing capabilities reflects global trends in pharmaceutical production, with a significant portion of API production and generic formulation occurring in India and China due to cost efficiencies and established infrastructure. However, regulatory compliance and quality assurance remain critical differentiating factors for manufacturers in all regions.

Key Takeaways

• Riluzole API production is concentrated among a few global players, primarily in China and India, with historical contributions from the U.S.
• Sanofi S.A. is the primary originator of Riluzole. A broad spectrum of generic manufacturers, notably from India, the U.S., and Europe, produce finished dosage forms.
• The patent landscape for Riluzole's core composition expired in the mid-2000s, leading to widespread generic market entry.
• Strict adherence to GMP, DMF/ASMF filings, pharmacopoeial standards, and country-specific registrations are mandatory regulatory requirements.
• Potential supply chain risks include API supplier concentration, quality control failures, logistical bottlenecks, geopolitical instability, and increasing regulatory scrutiny on impurity profiles.
• India and China are dominant manufacturing hubs for Riluzole API and generic formulations, with the U.S. and Europe also playing significant roles.

Frequently Asked Questions

1. Can Riluzole API be manufactured by any chemical company, or does it require specialized capabilities? Riluzole requires multi-step organic synthesis and adherence to stringent pharmaceutical quality standards (cGMP). This necessitates specialized chemical expertise, validated manufacturing processes, and robust quality control systems that not all chemical companies possess.

2. What is the typical shelf life of Riluzole tablets, and how is it determined? The typical shelf life of Riluzole tablets is generally between 24 to 36 months. This is determined through comprehensive stability studies conducted by the FDF manufacturer, which assess the drug product's quality attributes (e.g., potency, dissolution, impurity levels) over time under defined storage conditions (temperature and humidity).

3. Are there any significant upcoming patent expirations related to specific Riluzole formulations or delivery methods that could impact the market? The primary composition of matter patents have long expired. Any remaining patent protection would likely pertain to novel formulations, extended-release versions, or specific combination therapies. As of current knowledge, no major patents on novel delivery systems for Riluzole are poised for imminent expiry that would dramatically alter the generic landscape beyond the existing tablet market.

4. How do regulatory agencies ensure the quality and safety of Riluzole supplied from different global manufacturing sites? Regulatory agencies like the FDA and EMA conduct rigorous inspections of manufacturing facilities worldwide. They review Drug Master Files (DMFs) for API and Marketing Authorization Applications (MAAs)/ANDAs for finished products. Post-market surveillance, including adverse event reporting and targeted inspections, also plays a crucial role in ongoing quality assurance.

5. What are the primary impurity concerns for Riluzole API, and how are they controlled? Key impurity concerns often include process-related impurities (unreacted starting materials, intermediates, by-products) and degradation products. Manufacturers control these through optimized synthesis routes, stringent in-process controls, purification techniques (e.g., recrystallization, chromatography), and final product testing against pharmacopoeial limits. Regulatory agencies pay close attention to genotoxic impurities and nitrosamine impurities.

Citations

[1] U.S. Patent 4,732,906. (1986). 1,4-Benzothiazole derivatives. Assigned to Rhône-Poulenc S.A. [2] European Patent EP0128813B1. (1994). 1,4-Benzothiazole derivatives. Assigned to Rhône-Poulenc S.A. [3] U.S. Food and Drug Administration. (1995). Drug Approval Package: Rilutek (riluzole) Tablets. [4] U.S. Food and Drug Administration. Center for Drug Evaluation and Research. (Ongoing). Approved ANDAs. Retrieved from [FDA website]. [5] European Medicines Agency. (Ongoing). EudraGMDP Database. Retrieved from [EMA website]. [6] U.S. Pharmacopeia. (Ongoing). USP-NF Online. Retrieved from [USP website]. [7] European Pharmacopoeia. (Ongoing). EDQM Website. Retrieved from [EDQM website].